Table of Contents

An erratum for this article has been published. To view the erratum, please click here.

Chemotherapy Research and Practice
Volume 2012 (2012), Article ID 721873, 12 pages
Research Article

Methodology for Anti-Gene Anti-IGF-I Therapy of Malignant Tumours

1INSERM U542 and U602, Paul Brousse Hospital, Paris XI University, 16 Avenue. PV Couturier, 94807 Villejuif, France
2Laboratory of Gene Therapy, Faculty of Medicine, Cartagena's University, Cartagena de Indias, Colombia
3Faculty of Medicine, La Sabana University, Chia, Autopista Norte de Bogota, Colombia
4Department of General Medical Sciences, Case Western Reserve University, 2085 Adelbert Road, Cleveland, OH 44106, USA
5Cellvax, Veterinary National School, 7 Avenue General De Gaule, 94704 Maisons Alfort, France
6Laboratory of Cell Engineering, Cardiology Institute, Moscow University, Cherepkowskaya Street, Moscow 12 1552, Russia
7Department of Gene Therapy and Department of Neurosurgery, Collegium Medicum, Nicolas Copernic University, M. Curie Sklodowska Street, 85067 Bydgoszcz, Poland
8Laboratory of Neurobiology, Faculty of Science, Orleans' University, 45067 Orleans, France
9INSERM U930, Bretonneau Hospital, Tours' University, 2 Bd Tonnelle, 37044 Tours, France
10Laboratory of Molecular Diagnostic, Pablo Tobon Uribe Hospital, UPB University, Medellín, Colombia

Received 1 May 2011; Revised 25 October 2011; Accepted 31 October 2011

Academic Editor: Haruaki Tomioka

Copyright © 2012 Jerzy Trojan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The aim of this study was to establish the criteria for methodology of cellular “anti-IGF-I” therapy of malignant tumours and particularly for glioblastoma multiforme. The treatment of primary glioblastoma patients using surgery, radiotherapy, and chemotherapy was followed by subcutaneous injection of autologous cancer cells transfected by IGF-I antisense/triple helix expression vectors. The prepared cell “vaccines” should it be in the case of glioblastomas or other tumours, have shown a change of phenotype, the absence of IGF-I protein, and expression of MHC-I and B7. The peripheral blood lymphocytes, PBL cells, removed after each of two successive vaccinations, have demonstrated for all the types of tumour tested an increasing level of CD8+ and CD8+28+ molecules and a switch from CD8+11b+ to CD8+11. All cancer patients were supervised for up to 19 months, the period corresponding to minimum survival of glioblastoma patients. The obtained results have permitted to specify the common criteria for “anti-IGF-I” strategy: characteristics sine qua non of injected “vaccines” (cloned cells IGF-I(−) and MHC-I(+)) and of PBL cells (CD8+ increased level).